Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.190
+0.190 (9.50%)
At close: May 12, 2025, 4:00 PM
2.150
-0.040 (-1.83%)
After-hours: May 12, 2025, 4:28 PM EDT
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $162.81 million as of May 12, 2025. Its market cap has increased by 1,244.22% in one year.
Market Cap
162.81M
Enterprise Value
65.37M
1-Year Change
1,244.22%
Ranking
Category
Stock Price
$2.19
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $162.81M, an increase of 62.07%. That is a compound annual growth rate of 11.66%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 9, 2025 | 148.68M | -31.91% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 659.45B |
| Johnson & Johnson | 371.06B |
| UnitedHealth Group | 345.29B |
| AbbVie | 326.55B |
| Novo Nordisk | 297.79B |
| Abbott Laboratories | 231.82B |
| Novartis AG | 214.71B |
| AstraZeneca | 211.14B |